Patents Assigned to CS Pharmatech Limited
  • Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
    Patent number: 10435388
    Abstract: The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: October 8, 2019
    Assignee: CS Pharmatech Limited
    Inventors: Yuntao Song, Alexander James Bridges